ATE552842T1 - Verwendung von plasminogen zur wundheilung - Google Patents
Verwendung von plasminogen zur wundheilungInfo
- Publication number
- ATE552842T1 ATE552842T1 AT06126236T AT06126236T ATE552842T1 AT E552842 T1 ATE552842 T1 AT E552842T1 AT 06126236 T AT06126236 T AT 06126236T AT 06126236 T AT06126236 T AT 06126236T AT E552842 T1 ATE552842 T1 AT E552842T1
- Authority
- AT
- Austria
- Prior art keywords
- wound healing
- plasminogen
- healing
- relates
- tympanic membrane
- Prior art date
Links
- 230000029663 wound healing Effects 0.000 title abstract 3
- 102000013566 Plasminogen Human genes 0.000 title abstract 2
- 108010051456 Plasminogen Proteins 0.000 title abstract 2
- 206010045210 Tympanic Membrane Perforation Diseases 0.000 abstract 2
- 230000035876 healing Effects 0.000 abstract 2
- 208000032544 Cicatrix Diseases 0.000 abstract 1
- 206010052428 Wound Diseases 0.000 abstract 1
- 208000027418 Wounds and injury Diseases 0.000 abstract 1
- 238000010171 animal model Methods 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000001338 necrotic effect Effects 0.000 abstract 1
- 229940012957 plasmin Drugs 0.000 abstract 1
- 231100000241 scar Toxicity 0.000 abstract 1
- 230000037387 scars Effects 0.000 abstract 1
- 238000012216 screening Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/484—Plasmin (3.4.21.7)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Materials For Medical Uses (AREA)
- Manufacture Of Motors, Generators (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31764301P | 2001-09-06 | 2001-09-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE552842T1 true ATE552842T1 (de) | 2012-04-15 |
Family
ID=23234611
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT06126236T ATE552842T1 (de) | 2001-09-06 | 2002-09-06 | Verwendung von plasminogen zur wundheilung |
| AT02797695T ATE348631T1 (de) | 2001-09-06 | 2002-09-06 | Verwendung von plasminogen zur heilung von zerbrochenen trommelfellen |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02797695T ATE348631T1 (de) | 2001-09-06 | 2002-09-06 | Verwendung von plasminogen zur heilung von zerbrochenen trommelfellen |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US7067492B2 (de) |
| EP (2) | EP1427440B1 (de) |
| CN (2) | CN1961958B (de) |
| AT (2) | ATE552842T1 (de) |
| AU (1) | AU2002361878A1 (de) |
| DE (1) | DE60216939T2 (de) |
| DK (2) | DK1790354T3 (de) |
| ES (2) | ES2279001T3 (de) |
| WO (1) | WO2003020297A2 (de) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7067492B2 (en) * | 2001-09-06 | 2006-06-27 | Omnio Ab | Method of promoting healing of a tympanic membrane perforation |
| AU2006265601A1 (en) * | 2005-06-30 | 2007-01-11 | Anthrogenesis Corporation | Repair of tympanic membrane using placenta derived collagen biofabric |
| EP2441469A1 (de) * | 2006-03-14 | 2012-04-18 | Oregon Health and Science University | Verfahren zur Erzeugung einer Immunantwort auf Tuberculosis |
| WO2008021391A1 (en) | 2006-08-15 | 2008-02-21 | Anthrogenesis Corporation | Umbilical cord biomaterial for medical use |
| ES2453496T3 (es) * | 2006-08-28 | 2014-04-08 | Omnio Healer Ab | Diana farmacológica novedosa de prevención y tratamiento de enfermedad periodontal, mejora de la cicatrización de heridas periodontales y promoción de la salud oral |
| US8318661B2 (en) | 2006-08-28 | 2012-11-27 | Omnio Healer Ab | Candidates against infection |
| WO2008060377A2 (en) | 2006-10-04 | 2008-05-22 | Anthrogenesis Corporation | Placental or umbilical cord tissue compositions |
| KR20230146124A (ko) | 2006-10-06 | 2023-10-18 | 셀룰래리티 인코포레이티드 | 천연(텔로펩티드) 태반 콜라겐 조성물 |
| WO2008146224A2 (en) | 2007-05-25 | 2008-12-04 | Compex Medical S.A. | Wound healing electrode set |
| GB2450747A (en) * | 2007-07-06 | 2009-01-07 | Univ Sheffield | Treatment of sensorineural hearing loss |
| WO2009093970A1 (en) * | 2008-01-22 | 2009-07-30 | Omnio Healer Ab | Method of improving wound healing |
| RU2432397C2 (ru) * | 2009-11-24 | 2011-10-27 | Федеральное государственное учреждение "Российский кардиологический научно-производственный комплекс" Министерства здравоохранения и социального развития Российской Федерации (ФГУ "РКНПК" Минздравсоцразвития России) | РЕКОМБИНАНТНЫЙ ПОЛИПЕПТИД СО СВОЙСТВАМИ ПЛАЗМИНОГЕНА ЧЕЛОВЕКА ПРЕВРАЩАТЬСЯ ПРИ АКТИВАЦИИ В ПЛАЗМИН, КОТОРЫЙ КАТАЛИЗИРУЕТ РАСЩЕПЛЕНИЕ ФИБРИНА, ФРАГМЕНТ ДНК, КОДИРУЮЩИЙ ПОЛИПЕПТИД, РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК ДЛЯ ЭКСПРЕССИИ ПОЛИПЕПТИДА И ТРАНСФОРМИРОВАННАЯ КЛЕТКА Escherichia coli - ПРОДУЦЕНТ ПОЛИПЕПТИДА |
| RU2432396C2 (ru) * | 2009-11-24 | 2011-10-27 | Федеральное государственное учреждение "Российский кардиологический научно-производственный комплекс" Министерства здравоохранения и социального развития Российской Федерации (ФГУ "РКНПК" Минздравсоцразвития России) | РЕКОМБИНАНТНЫЙ ПОЛИПЕПТИД СО СВОЙСТВАМИ ПЛАЗМИНОГЕНА ЧЕЛОВЕКА ПРЕВРАЩАТЬСЯ ПРИ АКТИВАЦИИ В ПЛАЗМИН, КОТОРЫЙ КАТАЛИЗИРУЕТ РАСЩЕПЛЕНИЕ ФИБРИНА, ФРАГМЕНТ ДНК, КОДИРУЮЩИЙ ПОЛИПЕПТИД, РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК ДЛЯ ЭКСПРЕССИИ ПОЛИПЕПТИДА И ТРАНСФОРМИРОВАННАЯ КЛЕТКА Escherichia coli - ПРОДУЦЕНТ ПОЛИПЕПТИДА |
| EP3708181A1 (de) | 2013-05-15 | 2020-09-16 | The Board of Trustees of the Leland Stanford Junior University | Modulation der wirkung des heparin-bindenden epidermalem wachstumsfaktors zur wundheilung des trommelfells |
| TWI801331B (zh) * | 2015-11-03 | 2023-05-11 | 美商波麥堤克生物治療股份有限公司 | 纖維蛋白溶酶原缺乏症之纖維蛋白溶酶原替代療法 |
| TW201722464A (zh) * | 2015-11-10 | 2017-07-01 | 波麥堤克生化科學有限公司 | 用於傷口癒合之纖維蛋白溶酶原給藥方案 |
| ES2982294T3 (es) * | 2015-12-18 | 2024-10-15 | Talengen Int Ltd | Plasminógeno para su uso en el tratamiento o prevención de lesiones nerviosas por diabetes mellitus |
| CN108463240A (zh) * | 2015-12-18 | 2018-08-28 | 泰伦基国际有限公司 | 一种预防或治疗糖尿病性视网膜病变的方法 |
| DK3391902T5 (da) | 2015-12-18 | 2024-09-23 | Talengen Int Ltd | Plasminogen til anvendelse i behandlingen af diabetisk angiokardiopati |
| JP6793748B2 (ja) * | 2015-12-18 | 2020-12-02 | タレンゲン インターナショナル リミテッドTalengen International Limited | 放射性および化学的損傷を予防及び治療するための方法 |
| DK3395354T3 (da) | 2015-12-18 | 2024-06-03 | Talengen Int Ltd | Plasminogen til anvendelse i behandling af diabetisk nefropati |
| CN108463235A (zh) | 2015-12-18 | 2018-08-28 | 泰伦基国际有限公司 | 一种用于预防和治疗宫颈糜烂的方法 |
| US10590184B2 (en) * | 2016-09-26 | 2020-03-17 | National Yang-Ming University | Process for a preparation of the modified porcine plasma fibronectin for enhance wound healing |
| CN108210911A (zh) * | 2016-12-15 | 2018-06-29 | 深圳瑞健生命科学研究院有限公司 | 一种促进胰岛素分泌的方法 |
| CN110198732A (zh) | 2016-12-15 | 2019-09-03 | 泰伦基国际有限公司 | 一种促进胰岛素受体底物-2表达的方法 |
| JP7168990B2 (ja) | 2016-12-15 | 2022-11-10 | タレンゲン インターナショナル リミテッド | 肥満症を予防および治療するための方法および薬物 |
| JP7213552B2 (ja) | 2016-12-15 | 2023-01-27 | タレンゲン インターナショナル リミテッド | 肝の繊維化を予防及び治療するための方法 |
| TWI677348B (zh) * | 2016-12-15 | 2019-11-21 | 大陸商深圳瑞健生命科學研究院有限公司 | 一種改善心臟病變的方法 |
| WO2018107686A1 (zh) * | 2016-12-15 | 2018-06-21 | 深圳瑞健生命科学研究院有限公司 | 一种治疗动脉粥样硬化及其并发症的方法 |
| CN108210905A (zh) * | 2016-12-15 | 2018-06-29 | 深圳瑞健生命科学研究院有限公司 | 预防和治疗皮肤纤维化的药物及其用途 |
| CA3067890A1 (en) | 2017-06-19 | 2018-12-27 | Talengen International Limited | Method for regulating and controling glp-1/glp-1r and drug |
| CA3196851A1 (en) * | 2020-11-25 | 2022-06-02 | Grifols Worldwide Operations Limited | Wound healing |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU647391B2 (en) * | 1989-05-01 | 1994-03-24 | University Of Notre Dame Du Lac, The | Methods and materials for expression of human plasminogen in a eukaryotic cell system |
| US6197325B1 (en) * | 1990-11-27 | 2001-03-06 | The American National Red Cross | Supplemented and unsupplemented tissue sealants, methods of their production and use |
| US6559119B1 (en) * | 1990-11-27 | 2003-05-06 | Loyola University Of Chicago | Method of preparing a tissue sealant-treated biomedical material |
| DE69528573T2 (de) | 1995-01-27 | 2003-06-18 | Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno, Den Haag/S'gravenhage | Verwendung einer Zubereitung enthaltend einen Plasminogen-Aktivator für die Verbesserung der Wundheilung |
| CA2224253A1 (en) * | 1995-06-09 | 1996-12-27 | Martin J. Macphee | Chitin hydrogels, methods of their production and use |
| US6043407A (en) * | 1997-07-29 | 2000-03-28 | Warner-Lambert Company | Debridement pad |
| CA2352477A1 (en) * | 1998-11-25 | 2000-06-02 | Richard-Weidong Ji | Compositions comprising angiostatin and kringle 5 region of plasminogen and methods of use thereof |
| WO2000061179A1 (en) * | 1999-04-14 | 2000-10-19 | Karolinska Innovations Ab | Kringle domains of plasminogen, capable of modulating angiogenesis in vivo |
| US7067492B2 (en) * | 2001-09-06 | 2006-06-27 | Omnio Ab | Method of promoting healing of a tympanic membrane perforation |
| US7202066B2 (en) * | 2002-01-29 | 2007-04-10 | Carrington Laboratories, Inc. | Combination of a growth factor and a protease enzyme |
-
2002
- 2002-09-05 US US10/237,144 patent/US7067492B2/en not_active Expired - Lifetime
- 2002-09-06 AT AT06126236T patent/ATE552842T1/de active
- 2002-09-06 EP EP02797695A patent/EP1427440B1/de not_active Expired - Lifetime
- 2002-09-06 CN CN2006101318021A patent/CN1961958B/zh not_active Expired - Fee Related
- 2002-09-06 DE DE60216939T patent/DE60216939T2/de not_active Expired - Lifetime
- 2002-09-06 CN CNB02822230XA patent/CN1289145C/zh not_active Expired - Fee Related
- 2002-09-06 DK DK06126236.6T patent/DK1790354T3/da active
- 2002-09-06 ES ES02797695T patent/ES2279001T3/es not_active Expired - Lifetime
- 2002-09-06 EP EP06126236A patent/EP1790354B1/de not_active Expired - Lifetime
- 2002-09-06 AU AU2002361878A patent/AU2002361878A1/en not_active Abandoned
- 2002-09-06 WO PCT/IB2002/004206 patent/WO2003020297A2/en not_active Ceased
- 2002-09-06 DK DK02797695T patent/DK1427440T3/da active
- 2002-09-06 AT AT02797695T patent/ATE348631T1/de active
- 2002-09-06 ES ES06126236T patent/ES2387797T3/es not_active Expired - Lifetime
-
2005
- 2005-10-18 US US11/253,972 patent/US8637010B2/en active Active
-
2007
- 2007-11-30 US US11/947,952 patent/US8679482B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US20080090751A1 (en) | 2008-04-17 |
| CN1961958B (zh) | 2011-05-18 |
| EP1790354B1 (de) | 2012-04-11 |
| DK1790354T3 (da) | 2012-07-23 |
| DE60216939D1 (de) | 2007-02-01 |
| DE60216939T2 (de) | 2007-10-04 |
| WO2003020297A3 (en) | 2003-10-09 |
| CN1585649A (zh) | 2005-02-23 |
| EP1790354A2 (de) | 2007-05-30 |
| AU2002361878A1 (en) | 2003-03-18 |
| WO2003020297A2 (en) | 2003-03-13 |
| EP1790354A3 (de) | 2007-10-24 |
| EP1427440B1 (de) | 2006-12-20 |
| US20070041962A1 (en) | 2007-02-22 |
| CN1289145C (zh) | 2006-12-13 |
| DK1427440T3 (da) | 2007-04-30 |
| EP1427440A2 (de) | 2004-06-16 |
| ES2279001T3 (es) | 2007-08-16 |
| US8679482B2 (en) | 2014-03-25 |
| US20030147879A1 (en) | 2003-08-07 |
| US7067492B2 (en) | 2006-06-27 |
| ATE348631T1 (de) | 2007-01-15 |
| US8637010B2 (en) | 2014-01-28 |
| WO2003020297A8 (en) | 2004-07-08 |
| CN1961958A (zh) | 2007-05-16 |
| ES2387797T3 (es) | 2012-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE552842T1 (de) | Verwendung von plasminogen zur wundheilung | |
| DE60325770D1 (de) | Verwendung von rimexolon zur behandlung von augentrockenheit | |
| ATE376446T1 (de) | Verwendung von n-hydroxyalkyl-o-benzylchitosanen zur haarbehandlung | |
| DE60137430D1 (de) | Gewebeimplant zur wiederherstellung von knorpelgewebe | |
| DK1545587T3 (da) | Lactoferrinsammensætninger og fremgangsmåder til behandling af diabetiske sår | |
| EP1324780A4 (de) | Methoden zur behandlung von herzarrhythmie | |
| DE60101669T2 (de) | Verwendung von botulinum-toxin zur behandlung von diabetes | |
| DE60233955D1 (de) | Spezifische bindungsmittel von human angiopoietin-2 | |
| DE60112807D1 (de) | Zusammensetzung zur behandlung von durch arterielle irrigationsdefekt gewebeschäden | |
| ATE296628T1 (de) | Integrinhemmer zur behandlung von augenkrankheiten | |
| ATE452655T1 (de) | Verwendung von l-polynukleotiden zur diagnostischen bilderzeugung | |
| ATE515268T1 (de) | Verwendung von op-1 zur behandlung von knorpeldefekten | |
| DE60130661D1 (de) | Verwendung der 13-cis retinsäure zur behandlung von emphysemen | |
| DE60218153D1 (de) | Verwendung von proteasom-inhibitoren zur behandlung des trockenen auges | |
| DE50105735D1 (de) | Chlorzoxazon zur behandlung von psoriasis | |
| DE50205466D1 (de) | Substituierte 2,5-diamidoindole als ece-inhibitoren zur behandlung von kardiovaskulären erkrankungen | |
| DE60325194D1 (de) | Methoden zur verwendung von lamellaren körpern für therapeutische zwecke | |
| ATE402694T1 (de) | Verwendung von 1-phenyl-3-dimethylamino-propan- verbindungen zur therapie der harninkontinenz | |
| DE60223707D1 (de) | Calcium-l-threonat zur behandlung von knochenfrakturen | |
| DE50313329D1 (de) | 1-phenyl-2-dimethylaminomethylcyclohexanverbindungen zur therapie von depressiven symptomatiken, schmerz und inkontinenz | |
| DE60325496D1 (de) | Verwendung von dihydroimidazolonen zur behandlung von epilepsie bei hunden | |
| DE50111407D1 (de) | Mittel enthaltend n-chlortaurin sowie dessen verwendung zur behandlung von schleimhautpolypen | |
| DE69920015D1 (de) | Verfahren zur induktion der herstellung von wachstumsfaktoren | |
| ATE314066T1 (de) | Verwendung von buprenorphin zur therapie der harninkontinenz | |
| ATE353666T1 (de) | Verwendung von aktiviertem gerinnungsfaktor vii zur behandlung von durch thrombolytische therapie-induzierten wichtigen blutungen |